Trending Articles

article thumbnail

Open Source Healthcare – The Cure for Stagnant Medical Innovation

MedCity News

We are living in a moment when many realize that collaboration yields better, faster and more affordable advances. Open source also enables the potential for bigger profits and revenue. Whats in reach: a small amount of money paid for treatments across millions of people, rather than expensive lifesaving treatments only for the few who can afford them.

article thumbnail

Sustainability in Pharmaceutical Outsourcing

PharmaTech

Pharmaceutical Technology spoke with Saharsh Davuluri, Vice-Chairman and Managing Director, Neuland Laboratories, to see how the push to sustainability is impacting contract manufacturers.

article thumbnail

GSK backs £50m Oxford University cancer vaccine programme

pharmaphorum

A GSK alliance with Oxford University aims to identify precancerous changes in cells that could form the basis of preventive vaccines.

118
118
article thumbnail

An ALS treatment wave is approaching, and this biotech CEO is ready to surf

PharmaVoice

Coya Therapeutics is entering into a phase 2b study for its ALS, and the biotech’s CEO believes it’s on the cusp of a game changer.

105
105
article thumbnail

AI in Marketing & Sales: Today’s Tools, Tomorrow’s Potential

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

article thumbnail

Pfizer settles Biohaven kickback claims case for $59.7m

Pharmaceutical Technology

Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for preferential prescriptions.

article thumbnail

We Need to Talk About Hospice

MedCity News

It’s a place where compassion and dignity are paramount, where patients and families find solace and support during the most challenging times. We owe it to them to ensure that hospice care is of the highest quality, accessible to all and integrated into the broader continuum of care. The post We Need to Talk About Hospice appeared first on MedCity News.

Patients 108

More Trending

article thumbnail

Industry Outlook 2025: Through the Lens of a Service Provider

PharmaTech

Pharmaceutical Technology spoke with Adam Sherlock, CEO of Qinecsa, about the industry trends of 2024, the future technology agenda, and M&A prospects in 2025.

article thumbnail

Is federal funding frozen? Has it already thawed? Flip-flop leaves biopharma on edge

PharmaVoice

NIH grants that help fund drug development were caught in the mix of confusing executive orders this week.

article thumbnail

FDA approves Vertex’s acute pain treatment Journavx

Pharmaceutical Technology

The FDA has approved Vertex Pharmaceuticals oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

FDA 93
article thumbnail

MedCity FemFwd: Comparing Maternal Health in Employer-Sponsored Populations vs. Medicaid

MedCity News

In this episode, were joined by Emily Lindemer, an executive director at Morgan Health. Lindemer discusses a recent report she co-authored, which focuses on maternal health opportunities in employer-sponsored insurance. The post MedCity FemFwd: Comparing Maternal Health in Employer-Sponsored Populations vs. Medicaid appeared first on MedCity News.

Insurance 108
article thumbnail

5 Ways You Can Win Faster with Gen AI in Sales

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

article thumbnail

Ascentage raises $126m in first biotech IPO of 2025

pharmaphorum

China's Ascentage completes the first US biotech IPO of 2025, raising $126m for its pipeline of small-molecule cancer drugs.

98
article thumbnail

FDA approves new Alzheimer’s treatment regimen

PharmaTimes

Patients and care partners may find once every four weeks maintenance dosing easier

FDA 80
article thumbnail

European Drug Shortage Monitoring Platform Fully Operational

PharmaTech

The platform is live with full functionality for use by marketing authorization holders and national competent authorities to report drug supply information.

article thumbnail

Will European PFAS ban disrupt pharma supply chains?

Pharmaceutical Technology

A proposed ban on PFAS chemicals is being challenged over concerns about potential supply chain disruption in the pharmaceutical industry.

Pharma 72
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Are ICHRAs Actually Good for Employers and Employees?

MedCity News

ICHRAs are gaining a lot of interest in healthcare. Some say they are beneficial because they give employees more choice in their health insurance, while others are more skeptical. The post Are ICHRAs Actually Good for Employers and Employees? appeared first on MedCity News.

Insurance 111
article thumbnail

Could an ECG spot people at risk of cognitive decline?

pharmaphorum

UK Biobank study suggests someone's risk of premature ageing or cognitive decline could be predicted using a simple ECG reading supported by an AI

98
article thumbnail

Natural killer cells, a rising alternative to CAR-T cell therapy

PharmaVoice

These innate immune cells may provide a safer, lower-cost option in cancer and autoimmune diseases.

69
article thumbnail

Pharma Marketing in 2025: Talking Trends With Angela Tenuta

Eversana Intouch

In a rapidly evolving industry, staying ahead of the curve is critical. In PM360 ‘s article, What Is Pharma Marketing in 2025 ? Angela Tenuta, President, Full-Service Agencies, delves into the transformative trends shaping the future of pharmaceutical marketing. Applied AI Although AI promises a great return on investment, the pharma industry has been slow to adopt it due to ethical, regulatory, and compliance hurdles.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Tevogen Bio and Microsoft expand AI collaboration to PredicTcell tech

Pharmaceutical Technology

Tevogen Bio has expanded its partnership with Microsoft, aiming to further their collaboration centred on AI and advance PredicTcell.

69
article thumbnail

Safety Risk Sinks Cargo Therapeutics’ Cancer Cell Therapy Prospect, Leading to 50% Staff Cut

MedCity News

Phase 2 data for Cargo Therapeutics CD22-targeting cell therapy show low durability and cases of a severe immune response, some that were classified as grade 4 or 5 serious adverse events. Cargo is discontinuing the study and shifting focus to a different cell therapy on track to begin Phase 1 testing in mid-2025. The post Safety Risk Sinks Cargo Therapeutics Cancer Cell Therapy Prospect, Leading to 50% Staff Cut appeared first on MedCity News.

article thumbnail

Two more biotechs, Metsera and Maze, cross IPO finish line

pharmaphorum

Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.

95
article thumbnail

Vedanta Biosciences reveals Phase 2 VE303 results

PharmaTimes

Study highlights VE303's potential in reducing recurrent CDI

66
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Behind the Headlines: Sana’s Type 1 Diabetes Breakthrough, Drug Price Negotiations, and More

PharmaTech

Brian Feth, Jonathan Grinstein, PhD, Beth Willers, and Laks Pernenkil go behind the headlines to discuss major news announcements made during the JP Morgan Healthcare Conference, a wave of new Medicare drug price negotiations, and more.

article thumbnail

Takeda plans 2026 CEO succession

European Pharmaceutical Review

Christophe Weber is set to retire as Chief Executive Officer (CEO) of Takeda in June 2026 after 12 years.Julie Kim, president of Takedas US Business Unit has been appointed as Webers successor. Weber is the companys current President, CEO and representative director. He joined Takeda as CEO in April 2014. Two months later in June, he transitioned to the role of president and representative director.

article thumbnail

Medtech Startup Quibim Corrals $50M to Advance AI Analysis in Medical Imaging

MedCity News

Quibims technology applies artificial intelligence analysis to medical images to detect biomarkers. Hospitals and biopharma companies are among the startups customers, using its technology to analyze images to detect disease and guide clinical trial enrollment. The post Medtech Startup Quibim Corrals $50M to Advance AI Analysis in Medical Imaging appeared first on MedCity News.

Medical 103
article thumbnail

Ozempic is first GLP-1 drug FDA-approved for kidney disease

pharmaphorum

Novo Nordisk's Ozempic has become the first drug in the GLP-1 class to be cleared to prevent worsening kidney disease in type 2 diabetics

FDA 93
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

FDA Approves Suzetrigine, New Alternative to Opioids for Acute Pain

Pharmacy Times

The drug is a selective NaV1.8 pain signal inhibitor and is the first new class of medication to treat acute pain in over 20 years.

FDA 65
article thumbnail

Regulations in AI and Other Digital Technologies

PharmaTech

AI regulations in healthcare are rapidly evolving, and one should consult with regulatory subject matter experts, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.

article thumbnail

Bringing drugs to market has ‘never been more challenging,’ and pharma is learning to adapt

PharmaVoice

As changes to the U.S. regulatory foundation take hold, pharmas need to change their strategies to keep innovation — and the bottom line — above the surface.

Pharma 64
article thumbnail

DeepSeek v. ChatGPT: Why is healthcare so expensive in America? (Video)

MedCity News

The AI race heats up with a new kid on the block from China. How did it compare against a popular U.S. genAI engine on a simple healthcare industry question? The post DeepSeek v. ChatGPT: Why is healthcare so expensive in America? (Video) appeared first on MedCity News.

article thumbnail

10 Ways to Leverage Buyer Signals and Drive Revenue

In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.